Kirollos Hanna, PharmD, manager of Oncology Pharmacy at the University of Minnesota Medical Center, discusses the uptake of oncology biosimilars at his practice.
Kirollos Hanna, PharmD, manager of Oncology Pharmacy at the University of Minnesota Medical Center, discusses the uptake of oncology biosimilars at his practice.
Transcript
What has been your experience with the use of biosimilars in oncology at the University of Minnesota?
Hanna: Biosimilars have been around now for quite some time. And I think when biosimilars first rolled out, we really had some challenges and hurdles that we we had to really jump through from. It stemmed all the way from education, patient preference, institutional preference and what we really want to do. But I think now from where we are biosimilars have been integrated, really across the board for many of our patients with cancer, even those patients that do come to our infusion centers to receive a specialty infusions that may be for nononcology indications. Really they've become part of the standard of care. Our approach has been when we're evaluating a new biosimilar that comes to market. We do our analysis to our standard P&T [pharmacy and therapeutics] committees and all of that and really try to roll it out after we've done a full analysis of really how many biosimilars are available for that specific reference product, because what we don't want to do is that every year or every couple of years we go and have to reevaluate contracts, pricing, and things like that. But yeah, biosimilars, we've kind of hammered it down in terms of education. You know, physician buy-in and really their preferences. We have protocols that allow pharmacists to switch between reference products and biosimilars if a payer mandates one way or another, but I would say it's been a pretty positive rollout.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Getting to Know Dr Fabiola Molina, Hospitalist
February 26th 2024Fabiola Molina, MD, MHS, is a practicing hospitalist and assistant professor of medicine at Yale School of Medicine and Yale New Haven Hospital. An immigrant from Mexico, her experiences straddling 2 worlds, while attempting to navigate with her family the complicated safety-net system for health care in Texas, were key influences to her ardent focus on health equity.
Read More
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More